Literature DB >> 21282070

Activation of AKT in feline mammary carcinoma: a new prognostic factor for feline mammary tumours.

L Maniscalco1, S Iussich, J Martín de Las Mulas, Y Millán, B Biolatti, N Sasaki, T Nakagawa, R De Maria.   

Abstract

The PI3K/AKT/PTEN pathway is involved in the pathogenesis of several human cancers. This study investigated the biological and prognostic value of PI3K/AKT/PTEN pathway dysregulation in feline mammary tumours. Expression of p-AKT, HER2, PTEN and steroid receptors was assessed by immunohistochemistry (IHC) in 27 malignant and 12 benign mammary tumours from 39 female cats followed up over a 24-month period. Feline mammary carcinoma (FMC) cell lines were analyzed by Western blot and the feline AKT gene sequence was characterized. p-AKT expression statistically correlated with tumour malignancy, histological dedifferentiation and clinical recurrence. The animals with tumours expressing p-AKT had a shorter disease-free period than those with p-AKT-negative tumours. AKT activation was associated with HER2 expression and PTEN down-regulation, as occurs in human breast cancer, and feline AKT sequencing showed high homology with the human AKT gene. No AKT activation was observed in relation to either oestrogen receptor α (ERα) or progesterone receptor expression. Taken together, these data offer an explanation for AKT signalling and its role in FMC pathogenesis and prognosis, shedding new light on similarities between feline mammary tumours and hormone-independent breast cancer.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21282070     DOI: 10.1016/j.tvjl.2010.12.016

Source DB:  PubMed          Journal:  Vet J        ISSN: 1090-0233            Impact factor:   2.688


  14 in total

1.  St Gallen molecular subtypes in feline mammary carcinoma and paired metastases-disease progression and clinical implications from a 3-year follow-up study.

Authors:  M Soares; J Correia; M C Peleteiro; F Ferreira
Journal:  Tumour Biol       Date:  2015-10-20

2.  Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination.

Authors:  Heather M Gibson; Jesse J Veenstra; Richard Jones; Ulka Vaishampayan; Michele Sauerbrey; Gerold Bepler; Lawrence Lum; Joyce Reyes; Amy Weise; Wei-Zen Wei
Journal:  Cancer Immunol Res       Date:  2015-02-23       Impact factor: 11.151

3.  Identification of the interleukin-8 (CXCL-8) pathway in feline oral squamous cell carcinoma - A pilot study.

Authors:  Leah H Ackerman; Carlos H de Mello Souza; Galaxia Cortés-Hinojosa; Marc E Salute; Alexa A Stephen; Elizabeth Anthony; Keijiro Shiomitsu; Rowan J Milner
Journal:  Can J Vet Res       Date:  2022-01       Impact factor: 0.897

Review 4.  Evolution of animal models in cancer vaccine development.

Authors:  Wei-Zen Wei; Richard F Jones; Csaba Juhasz; Heather Gibson; Jesse Veenstra
Journal:  Vaccine       Date:  2015-08-01       Impact factor: 3.641

5.  HER2-Targeted Immunotherapy and Combined Protocols Showed Promising Antiproliferative Effects in Feline Mammary Carcinoma Cell-Based Models.

Authors:  Andreia Gameiro; Catarina Nascimento; Jorge Correia; Fernando Ferreira
Journal:  Cancers (Basel)       Date:  2021-04-21       Impact factor: 6.639

6.  The prognostic impact of Akt isoforms, PI3K and PTEN related to female steroid hormone receptors in soft tissue sarcomas.

Authors:  Andrej Valkov; Thomas K Kilvaer; Sveinung W Sorbye; Tom Donnem; Eivind Smeland; Roy M Bremnes; Lill-Tove Busund
Journal:  J Transl Med       Date:  2011-11-22       Impact factor: 5.531

7.  Serum HER2 levels are increased in cats with mammary carcinomas and predict tissue HER2 status.

Authors:  Maria Soares; Rita Ribeiro; Shabir Najmudin; Andreia Gameiro; Rita Rodrigues; Fátima Cardoso; Fernando Ferreira
Journal:  Oncotarget       Date:  2016-04-05

8.  Serum SDF-1 levels are a reliable diagnostic marker of feline mammary carcinoma, discriminating HER2-overexpressing tumors from other subtypes.

Authors:  Cláudia S Marques; Maria Soares; Ana Santos; Jorge Correia; Fernando Ferreira
Journal:  Oncotarget       Date:  2017-11-11

9.  Activation of mammalian target of rapamycin (mTOR) in triple negative feline mammary carcinomas.

Authors:  Lorella Maniscalco; Yolanda Millán; Selina Iussich; Mauro Denina; Raquel Sánchez-Céspedes; Francesca Gattino; Bartolomeo Biolatti; Nobuo Sasaki; Takayuki Nakagawa; Maria Flavia Di Renzo; Juana Martín de Las Mulas; Raffaella De Maria
Journal:  BMC Vet Res       Date:  2013-04-15       Impact factor: 2.741

10.  Triple-negative vimentin-positive heterogeneous feline mammary carcinomas as a potential comparative model for breast cancer.

Authors:  Diego Caliari; Valentina Zappulli; Roberta Rasotto; Barbara Cardazzo; Federica Frassineti; Michael H Goldschmidt; Massimo Castagnaro
Journal:  BMC Vet Res       Date:  2014-09-25       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.